跳到主要內容

臺灣博碩士論文加值系統

(44.200.194.255) 您好!臺灣時間:2024/07/16 11:36
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:鄭湜玄
研究生(外文):CHENG, SHIH-HSUAN
論文名稱:慢性阻塞性肺疾病病患短期使用系統性類固醇與發生靜脈血栓栓塞之風險相關性
論文名稱(外文):Risk of Venous Thromboembolism Associated with Short-Term Use of Systemic Corticosteroids among Patients with Chronic Obstructive Pulmonary Disease
指導教授:王孟廷
指導教授(外文):WANG, MENG-TING
口試委員:胡德民鮑力恒
口試委員(外文):HU, TEH-MINPAO, LI-HENG
口試日期:2020-05-11
學位類別:碩士
校院名稱:國防醫學院
系所名稱:藥學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2020
畢業學年度:108
語文別:中文
論文頁數:195
中文關鍵詞:系統性類固醇靜脈血栓栓塞慢性阻塞性肺疾病嵌入型案例對照研究
外文關鍵詞:Systemic CorticosteroidsVenous ThromboembolismChronic Obstructive Pulmonary DiseaseNested case-control study
相關次數:
  • 被引用被引用:0
  • 點閱點閱:173
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
第一章 緒言 1
第一節、研究緣起 1
第二節、研究目的 6
第三節、研究問題 7
第四節、研究假說 9
第二章 文獻回顧 10
第一節、慢性阻塞性肺疾病 10
第二節、系統性類固醇於慢性阻塞性肺疾病之治療角色 11
第三節、系統性類固醇引起凝血功能異常之相關性 13
第四節、長期系統性類固醇使用與靜脈血栓栓塞症風險相關之觀察型研究探討 15
第五節、短期系統性類固醇使用與靜脈血栓栓塞症風險相關之觀察型研究探討 19
第六節、評估慢性阻塞性肺疾病病患短期使用系統性類固醇與靜脈血栓栓塞症風險之重要性 29
第三章 材料與方法 32
第一節、資料來源 32
第二節、資料除錯 34
第三節、研究設計 37
第四節、鑑別研究世代 39
第五節、案例組與對照組之定義與選取 43
第六節、系統性類固醇之測量與操作型定義 45
第七節、干擾因子之測量及操作型定義 48
第八節、疾病風險分數的目的與建立 63
第九節、統計分析方法 64
第十節、樣本數估算 66
第十一節、次族群分析 68
第十二節、靈敏度試驗 69
第十三節、陰性對照 (negative control) 試驗 72
第十四節、人體試驗計畫審查 74
第四章 結果 75
第一節、研究世代概述 75
第二節、各研究變項於案例組與對照組之分佈情形 80
第三節、使用系統性類固醇藥物之使用時程與發生靜脈血栓栓塞症之風險評估 91
第四節、目前使用系統性類固醇藥物之連續使用天數與發生靜脈血栓栓塞症之風險評估 94
第五節、目前使用系統性類固醇藥物之平均日劑量與發生靜脈血栓栓塞症之風險評估 96
第六節、次族群分析結果 98
第七節、靈敏度試驗結果 101
第八節、陰性對照試驗結果 108
第五章 討論 110
第一節、研究結果之探討 110
第二節、研究之優點與限制 130
第六章 結論 134
第一節、研究結論 134
第二節、建議 135
第三節、總結 138
資料庫致謝 186
參考資料 187




1.Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at:https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed March 29, 2020.
2.World Health Organization. The top 10 causes of death. Available at:https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed March 21, 2020.
3.行政院衛生福利部.民國107年死因統計結果分析. Available at:https://dep.mohw.gov.tw/dos/lp-4472-113.html. Accessed March 21, 2020.
4.Soler-Cataluna J, Martínez-García MÁ, Sánchez PR, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
5.Zhang J, Zheng J, Huang K, et al. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514.
6.Ko FW, Chan KP. Acute exacerbation of COPD. Respirology. 2016;21(7):1152-1165.
7.台灣胸腔暨重症加護醫學會. 2019 肺阻塞臨床照護指引. Available at:https://www.tspccm.org.tw/media/7073. Accessed March 21, 2020.
8.Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173(3):R101-113.
9.Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
10.Di Nisio M, Van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060-3073.
11.Kim V, Goel N, Gangar J, et al. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2014;1(2):239.
12.Mejza F, Lamprecht B, Niżankowska-Mogilnicka E, et al. Arterial and venous thromboembolism in chronic obstructive pulmonary disease: from pathogenic mechanisms to prevention and treatment. Pneumonol Alergol Pol. 2015;83(6):485-494.
13.Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res. 2003;112(4):203-207.
14.Piazza G, Goldhaber SZ, Kroll A, et al. Venous thromboembolism in patients with chronic obstructive pulmonary disease. Am J Med. 2012;125(10):1010-1018.
15.Bertoletti L, Quenet S, Mismetti P, et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J. 2012;39(4):862-868.
16.Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers. 2015;1:15006.
17.Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3-10.
18.Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a us inflammatory bowel disease cohort. PloS One. 2016;11(6):e0158017.
19.Murthy SK, Nguyen GC. Increased risk of venous thromboembolic events with corticosteroid versus biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(1):166-167.
20.Lieber BA, Han J, Appelboom G, et al. Association of steroid use with deep venous thrombosis and pulmonary embolism in neurosurgical patients: a national database analysis. World Neurosurg. 2016;89:126-132.
21.Boylan MR, Perfetti DC, Elmallah RK, et al. Does chronic corticosteroid use increase risks of readmission, thromboembolism, and revision After THA? Clin Orthop Relat Res. 2016;474(3):744-751.
22.Buchanan IA, Lin M, Donoho DA, et al. Venous thromboembolism after degenerative spine surgery: a nationwide readmissions database analysis. World Neurosurg. 2019;125:e165-e174.
23.Kantar RS, Haddad AG, Tamim H, et al. Venous thromboembolism and preoperative steroid use: analysis of the NSQIP database to evaluate risk in surgical patients. Eur J Intern Med. 2015;26(7):528-533.
24.Rogers MAM, Lin P, Nallamothu BK, et al. Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: risks and mitigating factors. J Diabetes. 2018;10(7):546-555.
25.Sundboll J, Darvalics B, Horvath-Puho E, et al. Preadmission use of glucocorticoids and risk of cardiovascular events in patients with ischemic stroke. J Thromb Haemost. 2018;16(11):2175-2183.
26.Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
27.Sneeboer MMS, Hutten BA, Majoor CJ, et al. Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism. Thromb Res. 2016;140:46-50.
28.Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173(9):743-752.
29.Stuijver DJF, Majoor CJ, Van Zaane B, et al. Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest. 2013;143(5):1337-1342.
30.Sethi S, Mahler DA, Marcus P, et al. Inflammation in COPD: implications for management. Am J Med. 2012;125(12):1162-1170.
31.Lopez A, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397-412.
32.Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120.
33.Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci. 2003;72(14):1549-1561.
34.Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1941-1947.
35.Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177):456-460.
36.Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154(2):407-412.
37.Alía I, Miguel A, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med. 2011;171(21):1939-1946.
38.Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348(26):2618-2625.
39.Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43.
40.Ziegler R, Kasperk C. Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids. 1998;63(5-6):344-348.
41.Buttgereit F, Burmester G-R, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365(9461):801-803.
42.Price SR, Du J, Bailey JL, et al. Molecular mechanisms regulating protein turnover in muscle. Am J Kidney Dis. 2001;37(1):S112-S114.
43.Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. Arch Ophthalmol. 1963;70(4):482-491.
44.Sanders BP, Portman RJ, Ramey RA, et al. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol. 1992;89(4):816-821.
45.Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.
46.Schulze H, Shivdasani RA. Mechanisms of thrombopoiesis. J Thromb Haemost. 2005;3(8):1717-1724.
47.Jilma B, Cvitko T, Winter-Fabry A, et al. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost. 2005;94(4):797-801.
48.Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103(4):491-495.
49.Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118(2):247-252.
50.Van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483-2493.
51.Girolami A, Cosi E, Tasinato V, et al. Drug-induced thrombophilic or prothrombotic states: an underestimated clinical problem that involves both legal and illegal compounds. Clin Appl Thromb Hemost. 2017;23(7):775-785.
52.Sarlos P, Szemes K, Hegyi P, et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J Crohns Colitis. 2018;12(4):489-498.
53.McCurdy JD, Israel A, Hasan M, et al. A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(12):1493-1501.
54.Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007;45(2):335-341.
55.Buchanan IA, Lin M, Donoho DA, et al. Predictors of venous thromboembolism after nonemergent craniotomy: a nationwide readmission database analysis. World Neurosurg. 2019;122:e1102-e1110.
56.Majoor CJ, Kamphuisen PW, Zwinderman AH, et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J. 2013;42(3):655-661.
57.Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum. 2012;64(8):2753-2760.
58.Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167(9):935-943.
59.Putcha N, Drummond MB, Wise RA, et al. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575-91.
60.Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871.
61.Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-639.
62.Cao YQ, Dong LX, Cao J. Pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J. 2018;131(14):1732-1737.
63.Girolami A, De Marinis GB, Bonamigo E, et al. Arterial and venous thromboses in patients with idiopathic (immunological) thrombocytopenia: a possible contributing role of cortisone-induced hypercoagulable state. Clin Appl Thromb Hemost. 2013;19(6):613-618.
64.衛生福利資料科學中心. 兩百萬人檔相關介紹. Availible at:https://dep.mohw.gov.tw/DOS/cp-2506-3633-113.html. Accessed March 29, 2020.
65.Mann C. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20(1):54-60.
66.Etminan M. Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004;24(9):1105-1109.
67.Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
68.Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14.
69.Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229-238.
70.Ludvigsson JF, Inghammar M, Ekberg M, et al. A nationwide cohort study of the risk of chronic obstructive pulmonary disease in coeliac disease. J Intern Med. 2012;271(5):481-489.
71.Kinnunen T, Saynajakangas O, Tuuponen T, et al. Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med. 2003;97(2):143-146.
72.Alotaibi GS, Wu C, Senthilselvan A, et al. The validity of ICD codes coupled with imaging procedure codes for identifying acute venous thromboembolism using administrative data. Vasc Med. 2015;20(4):364-368.
73.Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359:j4323.
74.Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
75.Duggan DE, Yeh KC, Matalia N, et al. Bioavailability of oral dexamethasone. Clin Pharmacol Ther. 1975;18(2):205-209.
76.Derendorf H, Mollmann H, Barth J, et al. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol. 1991;31(5):473-476.
77.Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204.
78.Borvik T, Braekkan SK, Enga K, et al. COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J. 2016;47(2):473-481.
79.Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9-16.
80.Chung WS, Lin CL, Ho FM, et al. Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study. Eur Respir J. 2014;43(3):801-807.
81.Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93-102.
82.Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135-140.
83.Dabbagh O, Oza A, Prakash S, et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest. 2010;137(5):1145-1149.
84.Ungprasert P, Srivali N, Wijarnpreecha K, et al. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology. 2015;54(4):736-742.
85.Zhang R, Dong L, Shao F, et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry. 2011;44(5):183-188.
86.Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force. Ann Intern Med. 2002;136(9):680-690.
87.Martinez C, Suissa S, Rietbrock S, et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016;355:i5968.
88.MacDonald MR, Jhund PS, Petrie MC, et al. Discordant short-and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circ Heart Fail. 2008;1(4):234-241.
89.Tollanes MC, Wilcox AJ, Lie RT, et al. Familial risk of cerebral palsy: population based cohort study. BMJ. 2014;349:g4294.
90.Zoller B, Pirouzifard M, Memon AA, et al. Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case-control study from Sweden. Eur Respir J. 2017;49(2):1601014
91.O'Brien SH, Candrilli SD. In the absence of a central venous catheter, risk of venous thromboembolism is low in critically injured children, adolescents, and young adults: evidence from the national trauma data bank. Pediatr Crit Care Med. 2011;12(3):251-256.
92.White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.
93.Jonsson AK, Horvath-Puho E, Hagg S, et al. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol. 2009;1:19-26.
94.Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117(1):75-82.
95.Zoller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-249.
96.Higgins PD, Skup M, Mulani PM, et al. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13(2):316-321.
97.Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169(18):1677-1683.
98.Ungprasert P, Matteson EL, Crowson CS. Accuracy of diagnostic coding for sarcoidosis in electronic databases: a population-based study. Lung. 2017;195(6):713-715.
99.Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359:j4323.
100.Wang MT, Liou JT, Huang YW, et al. Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study. Thromb Haemost. 2016;115(6):1209-1219.
101.Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18(1):67-80.
102.陳致穎:評估慢性阻塞性肺疾病病患使用抗精神病藥物與發生靜脈血栓栓塞之風險相關性,國防醫學院藥學研究所碩士論文,2017年.
103.Aleva FE, Voets LW, Simons SO, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest. 2017;151(3):544-554.
104.Lipsitch M, Tchetgen ET, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383.
105.Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
106.Bartko J, Schoergenhofer C, Schwameis M, et al. Dexamethasone inhibits endotoxin-induced coagulopathy in human lungs. J Thromb Haemost. 2016;14(12):2471-2477.
107.De Kruif MD, Lemaire LC, Giebelen IA, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178(3):1845-1851.
108.Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-1124.
109.Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol. 2010;25(4):253-260.
110.Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente medical care program. Chest. 2005;128(4):2068-2075.
111.Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70.
112.Chen WJ, Lin CC, Lin CY, et al. Pulmonary embolism in chronic obstructive pulmonary disease: a population-based cohort study. COPD. 2014;11(4):438-443.
113.Chen CY, Liao KM. The incidence of deep vein thrombosis in Asian patients with chronic obstructive pulmonary disease. Medicine. 2015;94(44):e1741.
114.Schunemann HJ, Cushman M, Burnett AE, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225.
115.Kahn SR, Lim W, Dunn AS, et al. Prevention of vte in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.
116.Goldhaber SZ, Fanikos J. Prevention of deep vein thrombosis and pulmonary embolism. Circulation. 2004;110(16):e445-e447.
117.衛生福利部中央健康保險署. 2010年版_ICD-9-CM2001年版與ICD-10-CM/PCS對應資料檔. Available at:https://www.nhi.gov.tw/Content_List.aspx?n=53C4788D27A999C9&topn=23C660CAACAA159D. Accessed March 29, 2020.

電子全文 電子全文(網際網路公開日期:20250701)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top